-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, UJXli4/M1jOHLDwHsdDY4ySqEKPK8hyq7khOY9wEgp3B8WE+GanULMy6q2vAcUm4 GcoE+exDz8t/AzVjKpd2iQ== 0001013594-09-001232.txt : 20090617 0001013594-09-001232.hdr.sgml : 20090617 20090617172952 ACCESSION NUMBER: 0001013594-09-001232 CONFORMED SUBMISSION TYPE: SC 13D/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20090617 DATE AS OF CHANGE: 20090617 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: BIODELIVERY SCIENCES INTERNATIONAL INC CENTRAL INDEX KEY: 0001103021 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 352089858 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-57907 FILM NUMBER: 09897382 BUSINESS ADDRESS: STREET 1: 801 CORPORATE CENTER DRIVE STREET 2: SUITE 210 CITY: RALEIGH STATE: NC ZIP: 27607 BUSINESS PHONE: 919 582 9050 MAIL ADDRESS: STREET 1: 801 CORPORATE CENTER DRIVE STREET 2: SUITE 210 CITY: RALEIGH STATE: NC ZIP: 27607 FORMER COMPANY: FORMER CONFORMED NAME: MAS ACQUISITION XXIII CORP DATE OF NAME CHANGE: 20000111 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: ELLIOTT ASSOCIATES, L.P. CENTRAL INDEX KEY: 0000904495 STANDARD INDUSTRIAL CLASSIFICATION: UNKNOWN SIC - 0000 [0000] IRS NUMBER: 222140975 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D/A BUSINESS ADDRESS: STREET 1: 712 FIFTH AVENUE CITY: NEW YORK STATE: NY ZIP: 10019 BUSINESS PHONE: 2125062999 MAIL ADDRESS: STREET 1: 712 FIFTH AVE CITY: NEW YORK STATE: NY ZIP: 10019 FORMER COMPANY: FORMER CONFORMED NAME: ELLIOTT ASSOCIATES LP DATE OF NAME CHANGE: 19930513 SC 13D/A 1 bdsi13da-061709.htm JUNE 17, 2009

 


SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13D

(Rule 13d-101)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a)

(Amendment No. 1)*

BioDelivery Sciences International, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

09060J106

(CUSIP Number)

Stephen M. Schultz, Esq.

Kleinberg, Kaplan, Wolff & Cohen, P.C.

551 Fifth Avenue, New York, New York 10176

Tel: (212) 986-6000

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

June 4, 2009

(Date of Event Which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box o.

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 


 


1.

NAMES OF REPORTING PERSONS

I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

Elliott Associates, L.P.

2.

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

(a)

x

(b)

o

3.

SEC USE ONLY

4.

SOURCE OF FUNDS*

WC

5.

CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)      o

6.

CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

7.

SOLE VOTING POWER

4,075,350

8

SHARED VOTING POWER

0

9.

SOLE DISPOSITIVE POWER

4,075,350

10.

SHARED DISPOSITIVE POWER

0

11.

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

4,075,350

12.

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11)

 

EXCLUDES CERTAIN SHARES*  

o

13.

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

18.8%

14.

TYPE OF REPORTING PERSON*

PN

*SEE INSTRUCTIONS BEFORE FILLING OUT!

 


1.

NAMES OF REPORTING PERSONS

I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

Elliott International, L.P.

2.

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

(a)

x

(b)

o

3.

SEC USE ONLY

4.

SOURCE OF FUNDS*

WC

5.

CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)      o

6.

CITIZENSHIP OR PLACE OF ORGANIZATION

Cayman Islands, British West Indies

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

7.

SOLE VOTING POWER

0

8

SHARED VOTING POWER

262,845

9.

SOLE DISPOSITIVE POWER

0

10.

SHARED DISPOSITIVE POWER

262,845

11.

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

262,845

12.

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11)

 

EXCLUDES CERTAIN SHARES*  

o

13.

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

1.4%

14.

TYPE OF REPORTING PERSON*

PN

*SEE INSTRUCTIONS BEFORE FILLING OUT!

 


1.

NAMES OF REPORTING PERSONS

I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

Elliott International Capital Advisors Inc.

2.

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

(a)

x

(b)

o

3.

SEC USE ONLY

4.

SOURCE OF FUNDS*

OO

5.

CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)      o

6.

CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

7.

SOLE VOTING POWER

0

8

SHARED VOTING POWER

262,845

9.

SOLE DISPOSITIVE POWER

0

10.

SHARED DISPOSITIVE POWER

262,845

11.

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

262,845

12.

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11)

 

EXCLUDES CERTAIN SHARES*  

o

13.

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

1.4%

14.

TYPE OF REPORTING PERSON*

CO

*SEE INSTRUCTIONS BEFORE FILLING OUT!

 


This statement is filed with respect to the shares of the common stock, $0.001 par value (the “Common Stock”), of BioDelivery Sciences International, Inc. (the “Issuer”), beneficially owned by Elliott Associates, L.P. and its wholly-owned subsidiaries (“Elliott”), Elliott International, L.P. (“Elliott International”), and Elliott International Capital Advisers Inc. (“EICA” and collectively, the “Reporting Persons”) as of June 17, 2009 and amends and supplements the Schedule 13D filed on August 23, 2006 (the “Schedule 13D”). Except as set forth herein, the Schedule 13D is unmodified.

ITEM 1.

Security and Issuer.

Item 1 of the Schedule 13D has been supplemented by adding the following:

The Issuer’s principal executive office is located at 801 Corporate Center Drive, Suite 210, Raleigh, North Carolina, 27607.

ITEM 2.

Identity and Background.

Item 2 of the Schedule 13D has been supplemented by adding the following:

On June 4, 2009, the manager of CDC IV, LLC (“CDC”) delegated to Manchester Securities Corp. (“Manchester”), a wholly owned subsidiary of Elliott, all of its rights and authority with respect to the investment decisions relating to the Common Stock and the warrants to acquire Common Stock owned of record by CDC IV. Therefore, Elliott may be deemed to be the beneficial owner within the meaning of Rule 13d-3 of Common Stock and warrants to acquire Common Stock owned of record by CDC IV.

ITEM 5.

Interest in Securities of the Issuer.

(a)        Elliott owns 175,230 shares of Common Stock through a wholly-owned subsidiary, The Liverpool Limited Partnership. Elliott may also be deemed to be the beneficial owner of an additional 3,900,120 shares of Common Stock beneficially owned by CDC IV (the “CDC IV Shares”), consisting of: (i) 1,395,000 shares of Common Stock held by CDC IV and (ii) warrants held by CDC IV exercisable for 2,505,120 shares of Common Stock (“Warrants”). As described, above Manchester has investment discretion with respect to the CDC IV Shares and Warrants. Therefore, Elliott may be deemed to be the beneficial owner of an aggregate of 4,075,350 shares of Common Stock, constituting 18.8% of all of the outstanding shares of Common Stock.

Elliott International and EICA beneficially own an aggregate of 262,845 shares of Common Stock, constituting 1.4% of all of the outstanding shares of Common Stock.

The stock ownership reported in this paragraph (a) of Item 5 is as of June 17, 2009.

(b)        Elliott has the power to vote or direct the vote of, and to dispose or direct the disposition of, the shares of Common Stock beneficially owned by it.

Elliott International has the shared power with EICA to vote or direct the vote of, and to dispose or direct the disposition of, the shares of Common Stock owned by Elliott International. Information regarding each of Elliott International and EICA is set forth in Item 2 of this Schedule 13D and is expressly incorporated by reference herein.

(c)        A list of the transactions in the Issuer’s Common Stock that were effected by Elliott on behalf of CDC IV during the past sixty days is attached hereto as Appendix I.

 


(d)        Except for the CDC IV Shares and the Warrants, no person other than Elliott has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the shares of Common Stock beneficially owned by Elliott.

No person other than Elliott International and EICA has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the shares of Common Stock beneficially owned by Elliott International and EICA.

 

(e)

Not applicable.

ITEM 6.

Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.

Except as described in Item 2, there are no contracts, arrangements, understanding or relationships with respect to the securities of the Issuer among the Reporting Persons and any other person.

Item 7.

Material to Be Filed as Exhibits

The following documents are filed as exhibits:

Appendix I: List of the transactions in the Issuer’s Common Stock that were effected by the Reporting Persons during the past sixty days.

 


SIGNATURES

After reasonable inquiry and to the best of its knowledge and belief, the undersigned each certifies that the information with respect to it set forth in this statement is true, complete and correct.

Dated:

June 17, 2009

 

ELLIOTT ASSOCIATES, L.P.

By:        Elliott Capital Advisors, L.P., as General Partner

By:        Braxton Associates, Inc., as General Partner

 

By:  /s/  Elliot Greenberg

 

Elliot Greenberg,

Vice President

 

 

 

ELLIOTT INTERNATIONAL, L.P.

By:    Elliott International Capital Advisors Inc.,

as Attorney-in-Fact

 

By:  /s/  Elliot Greenberg

 

Elliot Greenberg,

Vice President

 

 

 

ELLIOTT INTERNATIONAL CAPITAL ADVISORS INC.

 

By:  /s/  Elliot Greenberg

 

Elliot Greenberg,

Vice President

 

 

 

 


APPENDIX I

LIST OF TRANSACTIONS

Transactions Effected by Manchester on behalf of CDC IV in Common Stock during the past sixty days:

 

Date of transaction

Amount of securities

Sold

Price per share or unit (excluding commissions)

Where and how the transaction was effected

06/15/09

39,263

$6.9000

Open Market

06/15/09

400

$6.9050

Open Market

06/15/09

100

$6.9100

Open Market

06/15/09

3,527

$6.9200

Open Market

06/15/09

423

$6.9300

Open Market

06/15/09

2,777

$6.9400

Open Market

06/15/09

5,100

$6.9500

Open Market

06/15/09

4,500

$6.9600

Open Market

06/15/09

200

$6.9650

Open Market

06/15/09

100

$6.9700

Open Market

06/15/09

11,600

$6.9800

Open Market

06/15/09

100

$6.9900

Open Market

06/15/09

31,694

$7.0000

Open Market

06/15/09

2,900

$7.0050

Open Market

06/15/09

5,100

$7.0100

Open Market

06/15/09

500

$7.0120

Open Market

06/15/09

300

$7.0125

Open Market

06/15/09

5,100

$7.0200

Open Market

06/15/09

2,800

$7.0300

Open Market

06/15/09

11,800

$7.1000

Open Market

06/15/09

5,988

$7.1100

Open Market

06/15/09

800

$7.1200

Open Market

06/15/09

100

$7.1300

Open Market

06/15/09

27,699

$7.2000

Open Market

06/15/09

1,300

$7.2050

Open Market

06/15/09

300

$7.2075

Open Market

06/15/09

3,779

$7.2100

Open Market

06/15/09

300

$7.2175

Open Market

06/15/09

1,700

$7.2200

Open Market

06/15/09

1,000

$7.2250

Open Market

06/15/09

5,900

$7.2275

Open Market

06/15/09

1,951

$7.2300

Open Market

06/15/09

400

$7.2350

Open Market

06/15/09

1,000

$7.2400

Open Market

06/15/09

2,000

$7.2475

Open Market

06/15/09

1,400

$7.2500

Open Market

06/15/09

85,586

$7.5000

Open Market

 

 


 

06/15/09

500

$7.5075

Open Market

06/15/09

18,968

$7.5100

Open Market

06/15/09

300

$7.5150

Open Market

06/15/09

600

$7.5175

Open Market

06/15/09

8,100

$7.5200

Open Market

06/15/09

200

$7.5250

Open Market

06/15/09

3,170

$7.5300

Open Market

06/15/09

680

$7.5400

Open Market

06/15/09

100

$7.5450

Open Market

06/15/09

7,459

$7.5500

Open Market

06/15/09

100

$7.5550

Open Market

06/15/09

3,400

$7.5800

Open Market

06/15/09

12,030

$7.6000

Open Market

06/15/09

8,650

$7.6100

Open Market

06/15/09

100

$7.6200

Open Market

06/15/09

700

$7.6300

Open Market

06/15/09

800

$7.6400

Open Market

06/15/09

10,800

$7.6500

Open Market

06/15/09

4,100

$7.6600

Open Market

06/15/09

300

$7.6800

Open Market

06/15/09

70

$7.6900

Open Market

06/15/09

300

$7.7550

Open Market

06/15/09

50

$7.7575

Open Market

06/15/09

1,550

$7.7800

Open Market

06/15/09

1,200

$7.7900

Open Market

06/15/09

1,600

$7.7950

Open Market

06/15/09

21,563

$7.8000

Open Market

06/15/09

300

$7.8050

Open Market

06/15/09

400

$7.8070

Open Market

06/15/09

300

$7.8075

Open Market

06/15/09

9,350

$7.8100

Open Market

06/15/09

500

$7.8200

Open Market

06/15/09

1,500

$7.8250

Open Market

06/15/09

1,150

$7.8275

Open Market

06/15/09

1,500

$7.8300

Open Market

06/15/09

2,750

$7.8325

Open Market

06/15/09

4,200

$7.8400

Open Market

06/15/09

700

$7.8450

Open Market

06/15/09

200

$7.8475

Open Market

06/15/09

1,327

$7.8500

Open Market

06/15/09

3,100

$7.8600

Open Market

06/15/09

100

$7.8650

Open Market

06/15/09

2,230

$7.8675

Open Market

06/15/09

800

$7.8700

Open Market

 

 


 

06/15/09

1,950

$7.8900

Open Market

06/15/09

7,470

$7.8950

Open Market

06/15/09

2,000

$7.8975

Open Market

06/15/09

1,810

$7.9000

Open Market

06/15/09

600

$7.9300

Open Market

06/15/09

850

$8.2500

Open Market

06/15/09

10,000

$8.2900

Open Market

06/15/09

4,036

$8.4002

Open Market

06/16/09

23,020

$6.3000

Open Market

06/16/09

1,980

$6.3100

Open Market

06/16/09

29,675

$6.3500

Open Market

06/16/09

200

$6.3600

Open Market

06/16/09

5,400

$6.3700

Open Market

06/16/09

12,949

$6.3800

Open Market

06/16/09

1,776

$6.4000

Open Market

06/16/09

25,000

$6.4500

Open Market

06/16/09

911

$6.4800

Open Market

06/16/09

14,589

$6.5000

Open Market

06/16/09

400

$6.5100

Open Market

06/16/09

28,148

$6.6000

Open Market

06/16/09

10,290

$6.6200

Open Market

06/16/09

4,651

$6.6500

Open Market

06/16/09

8,911

$7.0000

Open Market

06/16/09

100

$7.0100

Open Market

06/16/09

1,000

$7.0200

Open Market

 

 

 

-----END PRIVACY-ENHANCED MESSAGE-----